Clinical trials: Hypertension, Uncontrolled
Primary Open-angle Glaucoma, Cataract
MINIject Implantation Combined With Cataract Surgery in Patients With POAG and Cataract
The study will assess safety and performance of MINIject implant in patients with open-angle glaucoma uncontrolled by topical hypotensive medications in conjunction with cataract surgery.
- Trial name
- STAR-VI (NCT05432245)
- Testing
- Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)
- Where
- 4 sites in Panama, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- iSTAR Medical
Arterial Hypertension
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients
- Trial name
- NCT01071681
- Testing
- Telmisartan (Kinzal/Pritor, BAY68-9291)
- Where
- France
- Volunteers
- 1,589 people
- Sponsor
- Bayer
Primary Open-angle Glaucoma
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
Objectives: To evaluate the non-inferiority in the intraocular pressure decrease of the preservative-free ophthalmic solution PRO-122, manufactured by Laboratorios Sophia S.A.
- Trial name
- PRO-122LATAM (NCT03193333)
- Testing
- PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic
- Where
- 2 sites in Colombia, Mexico
- Volunteers
- 51 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Essential Hypertension
To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT06465264
- Testing
- Allisartan Isoproxil/Amlodipine group 1, Amlodipine group 1, Allisartan Isoproxil/Amlodipine group 2
- Where
- China
- Volunteers
- 499 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide
Recruiting in Germany only: This study will evaluate the safety and efficacy of valsartan plus HCTZ in fixed dose combination in hypertensive patients not responding to treatment with the free combination of Candesartan plus…
- Trial name
- NCT00360178
- Testing
- Valsartan plus Hydrochlorothiazide, Candesartan plus Hydrochlorothiazide, Amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 198 people
- Sponsor
- Novartis
Uncontrolled Hypertension, Resistant Hypertension
A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase II, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, and effect of low, middle and high dose of SAL0120 versus placebo, administered once daily (QD) orally…
- Trial name
- NCT07790120
- Testing
- SAL0120
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Glaucoma
Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav
The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.
- Trial name
- NCT00519753
- Testing
- Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)
- Where
- Germany
- Volunteers
- 522 people
- Sponsor
- Alcon Research
Uncontrolled Hypertension
A Study of CIN-107 in Patients With Uncontrolled Hypertension
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of multiple dose strengths of baxdrostat (also called CIN-107) in the treatment of patients with uncontrolled hypertension.
- Trial name
- HALO (NCT05137002)
- Testing
- CIN-107
- Where
- 63 sites in United States
- Volunteers
- 249 people
- Sponsor
- CinCor Pharma, Inc.
Open Angle Glaucoma, Ocular Hypertension
MINIject Global Long-Term Follow-up Study
The study will assess the long-term (up to 5 years) safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.
- Trial name
- STAR-GLOBAL (NCT04524416)
- Testing
- Minimally invasive glaucoma surgery (MIGS)
- Where
- 9 sites in Colombia, France and 4 more
- Volunteers
- 116 people
- Sponsor
- iSTAR Medical
Uncontrolled Hypertension
Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
An international, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation in patients with uncontrolled hypertension.
- Trial name
- HTN-2 (NCT00888433)
- Testing
- Renal Denervation (Symplicity® Renal Denervation System)
- Where
- 20 sites in Australia, Austria and 8 more
- Volunteers
- 106 people
- Sponsor
- Medtronic Vascular
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Hypertension, CKD - Chronic Kidney Disease
A Randomized Trial of Six-Channel RF Ablation System for Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease
Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of the six-channel radiofrequency（RF) renal denervation system-comprising the six-channel radiofrequency…
- Trial name
- NCT07130955
- Testing
- Six-channel RF Renal Denervation System
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Hypertension, Uncontrolled Hypertension
SMART Study in Real World
This study is a multicenter, single-arm, open-label and post-market study in a real world patient population with uncontrolled hypertension to document the long-term safety and efficacy of a renal mapping/selective renal…
- Conditions
- Hypertension, Uncontrolled Hypertension, Resistant Hypertension, Reduce Antihypertensive Drug Burden
- Trial name
- SMART-RW (NCT06780696)
- Testing
- SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Uncontrolled Hypertension
Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension
The objective of this study is to demonstrate that the MDT-2211 renal denervation system is a safe and effective treatment for uncontrolled hypertension subjects despite treatment with 3 or more anti-hypertensive medications of…
- Trial name
- HTN-J (NCT01644604)
- Testing
- MDT-2211 Renal Denervation System
- Where
- 17 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Medtronic Vascular
Hypertension
Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients
The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.
- Trial name
- NCT01602367
- Testing
- BMS-823778
- Where
- 35 sites in United States, Colombia and 3 more
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Hypertension, Vascular Diseases
DENEX, Renal Denervation Therapy, in Patients With Hypertension on no or 1-3 Antihypertensive Medications
The objective of this study is to show that the safety and efficacy of renal denervation using DENEX, are superior to those of control group for the patients with hypertension on no or 1 to 3 antihypertensive medications.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT04307836
- Testing
- Renal Denervation
- Where
- 30 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Kalos Medical
Uncontrolled Essential Hypertension
Ultrasound Ablation for Essential Hypertension（FIM）
To evaluate the safety and feasibility of disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument in the treatment of essential hypertension.
- Trial name
- NCT05795829
- Testing
- disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Hypertension
MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)
This study has two parts. In the first part, the efficacy and safety MK-0954E (losartan potassium 50 mg [L50] (+) hydrochlorothiazide 12.5 mg [H12.5] (+) amlodipine besylate 5mg [A5]) will be evaluated and compared to the…
- Trial name
- NCT01299376
- Testing
- L50/H12.5/A5, L50/H12.5
- Volunteers
- 286 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol
The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01336569
- Testing
- Travoprost 0.004%/timolol maleate 0.5% fixed combination
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Hypertension, Diabetes Mellitus, Type 2
Proteus Discover in Subjects With Uncontrolled Hypertension and Type 2 Diabetes
The purpose of this study was to evaluate the efficacy of a new digital health offering, Proteus Discover to lower blood pressure and glycated hemoglobin in patients with uncontrolled hypertension and type 2 diabetes.
- Conditions
- Hypertension, Diabetes Mellitus, Type 2, Hypercholesterolemia
- Trial name
- NCT02827630
- Testing
- Proteus Discover, Usual Care
- Volunteers
- 118 people
- Sponsor
- Proteus Digital Health, Inc.